Celltrion Applies for European Approval of Humira Biosimilar

gloved hand withdraws drug solution with syringe

The Korean Herald reported today that Celltrion has applied for the European Medicine Agency’s approval of CT-P17, a Humira (adaliumumab) biosimilar.  According to the Korean Herald, Celltrion “expects to introduce CT-P17 to the European market in about a year’s time, which is how long the EMA typically takes to review.”  The article reports that, “[d]ue to its high potency, CT-P17 can have its targeted effect with less amount of injection than the original” and that CT-P17 “is citrate-free, meaning it causes less pain upon injection.”